sulfadiazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-infectives, sulfonamides 2500 68-35-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulfadiazine sodium
  • sulfadiazine
  • sulfadiazin
  • sulfapyrimidine
  • sulfazine
  • sulphadiazine
One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
  • Molecular weight: 250.28
  • Formula: C10H10N4O2S
  • CLOGP: 0.10
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 97.97
  • ALOGS: -2.62
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.13 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 57 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 684.95 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.29 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.55 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.44 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 11, 1941 FDA LEDERLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipase increased 215.61 31.56 50 1564 9850 63477558
Drug hypersensitivity 196.36 31.56 112 1502 310575 63176833
Pancreatitis 140.29 31.56 51 1563 49004 63438404
Drug reaction with eosinophilia and systemic symptoms 92.22 31.56 34 1580 33802 63453606
Pancytopenia 58.01 31.56 34 1580 96899 63390509
Pneumonia aspiration 43.51 31.56 20 1594 34520 63452888
Astigmatism 43.29 31.56 9 1605 1058 63486350
Bone marrow failure 40.17 31.56 18 1596 29272 63458136
Coma 39.57 31.56 23 1591 64341 63423067
Hepatocellular injury 38.10 31.56 17 1597 27364 63460044
Cerebral toxoplasmosis 32.52 31.56 7 1607 971 63486437
Infection protozoal 32.09 31.56 4 1610 15 63487393
Underdose 31.78 31.56 15 1599 27441 63459967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 88.52 27.34 34 1520 21612 34933765
Cerebral toxoplasmosis 43.77 27.34 11 1543 1710 34953667
Stevens-Johnson syndrome 41.45 27.34 19 1535 18620 34936757
Pulmonary venous thrombosis 35.20 27.34 6 1548 135 34955242
Pulmonary vasculitis 32.04 27.34 7 1547 592 34954785
Central pain syndrome 31.58 27.34 5 1549 70 34955307
Drug hypersensitivity 31.31 27.34 27 1527 80502 34874875
Neuritis 28.95 27.34 7 1547 927 34954450
Electric shock 27.82 27.34 5 1549 154 34955223

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 95.11 25.16 46 2766 64198 79677378
Toxic epidermal necrolysis 75.38 25.16 35 2777 44546 79697030
Pancytopenia 74.58 25.16 55 2757 165690 79575886
Cerebral toxoplasmosis 73.55 25.16 17 2795 2345 79739231
Drug hypersensitivity 46.76 25.16 55 2757 298861 79442715
Astigmatism 39.38 25.16 9 2803 1180 79740396
Pulmonary venous thrombosis 35.90 25.16 6 2806 152 79741424
Pulmonary vasculitis 31.98 25.16 7 2805 754 79740822
Hepatocellular injury 31.30 25.16 20 2792 47573 79694003
Infection protozoal 30.38 25.16 4 2808 17 79741559
Bone marrow failure 30.00 25.16 20 2792 51087 79690489
Neurological symptom 28.60 25.16 11 2801 8772 79732804
Pneumonia aspiration 27.31 25.16 21 2791 66946 79674630
Neuritis 26.16 25.16 7 2805 1751 79739825
Central pain syndrome 25.71 25.16 5 2807 301 79741275
Coma 25.50 25.16 24 2788 100625 79640951

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01EC02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
SULFONAMIDES AND TRIMETHOPRIM
Intermediate-acting sulfonamides
ATC J01EE02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
SULFONAMIDES AND TRIMETHOPRIM
Combinations of sulfonamides and trimethoprim, incl. derivatives
ATC J01EE06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
SULFONAMIDES AND TRIMETHOPRIM
Combinations of sulfonamides and trimethoprim, incl. derivatives
FDA CS M0020790 Sulfonamides
FDA EPC N0000175503 Sulfonamide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D003049 Coccidiostats
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:35818 coccidiostats
CHEBI has role CHEBI:35820 antiprotozoal drugs
CHEBI has role CHEBI:50502 dihydropteroate synthase inhibitors
CHEBI has role CHEBI:74234 sepiapterin reductase inhibitors
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chorioretinitis indication 46627006 DOID:8886
Skin ulcer indication 46742003
Ulcerative colitis indication 64766004 DOID:8577
Congenital toxoplasmosis indication 73893000 DOID:13336
Toxoplasmosis indication 187192000 DOID:9965
Toxoplasmosis associated with acquired immunodeficiency syndrome indication 421666009
Rheumatic Fever Prevention indication
Burn Wound Infections indication
Encephalitis due to Toxoplasmosis indication
Minor Bacterial Skin Infections indication
Collagenous colitis off-label use 19311003 DOID:0060183
Psoriasis with arthropathy off-label use 33339001
Crohn's disease off-label use 34000006
Rheumatoid arthritis off-label use 69896004 DOID:7148
Systemic sclerosis off-label use 89155008 DOID:418
Juvenile rheumatoid arthritis off-label use 410795001
Toxoplasmosis Prevention off-label use
Urinary tract obstruction contraindication 7163005 DOID:5200
Third trimester pregnancy contraindication 41587001
Leukopenia contraindication 84828003 DOID:615
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Gastrointestinal obstruction contraindication 126765001
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Superimposed infection contraindication 193198003
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Systemic antibacterial action against sensitive organisms to surgery Indication
Dogs Systemic antibacterial action against sensitive organisms to debridement Indication
Dogs Control of bacterial infection during the treatment of acute urinary tract infections Indication
Dogs Control of bacterial infection during the treatment of acute bacterial complications of distemper Indication
Dogs Control of bacterial infection during the treatment of acute respiratory tract infections Indication
Dogs Control of bacterial infection during the treatment of acute alimentary tract infections Indication
Dogs Control of bacterial infection during the treatment of wound infections Indication
Dogs Control of bacterial infection during the treatment of abscesses Indication
Horses Systemic antibacterial action against sensitive organisms during treatment of acute strangles Indication
Horses Systemic antibacterial action against sensitive organisms during respiratory infections Indication
Horses Systemic antibacterial action against sensitive organisms during acute urogenital infections Indication
Horses Systemic antibacterial action against sensitive organisms during wound infections Indication
Horses Systemic antibacterial action against sensitive organisms during abscesses Indication

🐶 Veterinary products

ProductApplicantIngredients
Tribrissen 120 Tablets, Tribrissen 30 Tablets, Tribrissen 480 Tablets, Tribrissen 960 Tablets Intervet Inc. 2
Tribrissen 24% Injection Intervet Inc. 2
Tribrissen 48% Injection Intervet Inc. 2
Di-Trim Tablets Zoetis Inc. 2
Tribrissen 400 Oral Paste Intervet Inc. 2
Di-Trim 24% Zoetis Inc. 2
Di-Trim 48% Injection Zoetis Inc. 2
Di-Trim 400 Paste Zoetis Inc. 2
Tribrissen 60 Oral Suspension Intervet Inc. 2
ReBalance Pegasus Laboratories Inc. 2
EQUISUL-SDT Aurora Pharmaceutical Inc. 2
Uniprim Powder Neogen Corp. 2
Tucoprim Powder Zoetis Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.6 acidic
pKa2 2.03 Basic
pKa3 1.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR IC50 6.03 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR IC50 4.96 WOMBAT-PK
Aurora kinase A Kinase IC50 4.68 CHEMBL
High affinity choline transporter 1 Transporter IC50 4.24 WOMBAT-PK
Dihydropteroate synthase Enzyme INHIBITOR CHEMBL CHEMBL
Dihydroorotate dehydrogenase (quinone), mitochondrial Enzyme WOMBAT-PK

External reference:

IDSource
D00587 KEGG_DRUG
547-32-0 SECONDARY_CAS_RN
4017497 VANDF
C0038675 UMLSCUI
CHEBI:9328 CHEBI
CHEMBL439 ChEMBL_ID
CHEMBL1200351 ChEMBL_ID
DB00359 DRUGBANK_ID
D013411 MESH_DESCRIPTOR_UI
5215 PUBCHEM_CID
12635 IUPHAR_LIGAND_ID
421 INN_ID
0N7609K889 UNII
10171 RXNORM
13920 MMSL
2022 MMSL
5523 MMSL
7798 MMSL
87818 MMSL
d00118 MMSL
002814 NDDF
014626 NDDF
371400009 SNOMEDCT_US
74523009 SNOMEDCT_US
768490003 SNOMEDCT_US
422 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sulfadiazine HUMAN PRESCRIPTION DRUG LABEL 1 0185-0757 TABLET 500 mg ORAL ANDA 18 sections
SULFADIAZINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-757 TABLET 500 mg ORAL ANDA 19 sections